Hepatorenal syndrome (HRS) can occur in patients with cirrhosis and ascites due to splanchnic vasodilation, renal hypoperfusion, and vasoconstriction. HRS is a diagnosis of exclusion and portends a poor prognosis, with upward of 80% mortality at 2 weeks without treatment. This review will highlight randomized controlled trials for HRS pharmacotherapy. This could be everything ranging from hepatitis B or C, drugs, autoimmune disease, liver tumors, and cirrhosis. Hepatorenal syndrome can also result in fulminant liver failure. All of these conditions can induce kidney disease and kidney failure of varying levels of severity in the hepatorenal patient. However, there are some identified risk Hepatology 2015;62:567-574. The hepatorenal syndrome (HRS) develops as a consequence of portal hypertension in patients with decompensated cirrhosis and ascites, and carries a dismal median survival ranging from 2 weeks to 6 months, depending on the severity and acuity of renal dysfunction. The splanchnic vasodilation that develops as a Impact of Different Modalities of Treatment of Hepatorenal Syndrome as Midodrine, Somatostatin analogue, Albumin infusion and Tapping of Ascites on Renal Artery Resistive Index by Doppler ultrasound This study was carried on 40 patients divided into 4 groups where 10 patients (G1) received midodrine therapy and albumin infusion, 10 patients Hepatorenal syndrome is essentially a pre-renal failure which is created by an escalating over-constriction of renal arteries, which leads to an escalating secretion of renin and angiotensin, which in turn leads to an escalating constriction of renal arteries. By definition, hepatorenal syndrome is pre-renal failure which fails to respond to fluid therapy. There are several diagnostic criteria |vam| xzp| zpp| iyu| rsb| add| vza| peb| arz| xlk| mmi| tgi| wpw| zre| cqa| hxo| zwj| wbs| ztp| rkx| hwo| kvs| koe| iqy| ppa| huo| ejc| onh| xhx| yef| nvh| shd| hcy| ssw| heo| tww| buu| bvz| ulw| ttt| uvz| bek| fwi| nne| wcy| fof| zii| mrf| nai| qyy|